Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats

Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-partic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Life sciences (1973) 2018-06, Vol.203, p.129-140
Hauptverfasser: Farrag, S.M., Hamzawy, M.A., El-Yamany, M.F., Saad, M.A., Nassar, N.N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 140
container_issue
container_start_page 129
container_title Life sciences (1973)
container_volume 203
creator Farrag, S.M.
Hamzawy, M.A.
El-Yamany, M.F.
Saad, M.A.
Nassar, N.N.
description Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-particulate formulation in alleviating the muscles and liver damage either alone or when co-administered with nano coenzyme Q10 and nano vitamin E. Male Wistar rats were fed normal diet or high-fat diet for 12 weeks, following which rats were treated with either (i) atorvastatin (5 or 20 mg/kg/day, p.o.) or (ii) atorvastatin with CoQ10 (10 mg/kg/day, p.o.) (iii) and/or vitamin E (30 mg/kg/day, p.o.) in free particle or nanoparticle forms for another 4 weeks. In all rats, serum total cholesterol (CH), triglycerides (TGs), low (LDL) and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (ALP), creatine kinase (CK), albumin (ALB), as well as hepatic malondialdehyde (MDA) and antioxidants “reduced glutathione (GSH) and superoxide dismutase (SOD)” were measured. Additionally quadriceps muscles and liver tissues were used for histopathological examination. The antihyperlipidemic effect of statins was not altered when formulated as nanoparticles; albeit the former showed a prominent reduction in the liver and muscle enzymes and histopathological alterations together with a marked decline in the oxidative stress as compared to the free particulate form. These results were augmented when atorvastatin was combined with CoQ10 and/or Vit.E. Nanoparticulate formulation alleviated the statins induced liver and muscle damage especially when combined with CoQ10 and/or Vit.E.
doi_str_mv 10.1016/j.lfs.2018.04.034
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2031421742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320518302157</els_id><sourcerecordid>2031421742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-d2dbdafd1b541aeb6cb6b9f07d7c2c3fd05be02c3dec85b0e0f5ded3a7c9f7a83</originalsourceid><addsrcrecordid>eNp9kc2KFTEQhRtRnOvoA7iRgBs33VPp9C-uhmH8gQERdB3SSYWbSzppk_Qdrk8yj2vaO7pwIQRSCd85VdQpitcUKgq0uzpUVseqBjpU0FTAmifFjg79WELH6NNiB1A3JauhvShexHgAgLbt2fPioh67sRkY3RUP18mHo4hJJONIPk44Xy4iJCNXKxIS7cO8VcY7Iqb8E8m8RmmRCKeINUcMRGhtjfyN3O_REemFxShRkXuT9vmJ7udpRvKVwqa68oEcTRJz7ne7Nd2fFgzWLEbhbCQJIsWXxTMtbMRXj_dl8f3D7bebT-Xdl4-fb67vSskGmkpVq0kJrejUNlTg1Mmpm0YNveplLZlW0E4IuVIoh3YCBN0qVEz0ctS9GNhl8e7suwT_Y8WY-Gzy5NYKh36NvAZGm5r2TZ3Rt_-gB78Gl6fLVE8ZNF3HMkXPlAw-xoCaL8HMIpw4Bb7Fxg88x8a32Dg0PMeWNW8enddpRvVX8SenDLw_A5hXcTQYeJQGXd6wCSgTV978x_4XN-ysew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2071304663</pqid></control><display><type>article</type><title>Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Farrag, S.M. ; Hamzawy, M.A. ; El-Yamany, M.F. ; Saad, M.A. ; Nassar, N.N.</creator><creatorcontrib>Farrag, S.M. ; Hamzawy, M.A. ; El-Yamany, M.F. ; Saad, M.A. ; Nassar, N.N.</creatorcontrib><description>Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-particulate formulation in alleviating the muscles and liver damage either alone or when co-administered with nano coenzyme Q10 and nano vitamin E. Male Wistar rats were fed normal diet or high-fat diet for 12 weeks, following which rats were treated with either (i) atorvastatin (5 or 20 mg/kg/day, p.o.) or (ii) atorvastatin with CoQ10 (10 mg/kg/day, p.o.) (iii) and/or vitamin E (30 mg/kg/day, p.o.) in free particle or nanoparticle forms for another 4 weeks. In all rats, serum total cholesterol (CH), triglycerides (TGs), low (LDL) and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (ALP), creatine kinase (CK), albumin (ALB), as well as hepatic malondialdehyde (MDA) and antioxidants “reduced glutathione (GSH) and superoxide dismutase (SOD)” were measured. Additionally quadriceps muscles and liver tissues were used for histopathological examination. The antihyperlipidemic effect of statins was not altered when formulated as nanoparticles; albeit the former showed a prominent reduction in the liver and muscle enzymes and histopathological alterations together with a marked decline in the oxidative stress as compared to the free particulate form. These results were augmented when atorvastatin was combined with CoQ10 and/or Vit.E. Nanoparticulate formulation alleviated the statins induced liver and muscle damage especially when combined with CoQ10 and/or Vit.E.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2018.04.034</identifier><identifier>PMID: 29694831</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Alanine ; Alkaline phosphatase ; Antioxidants ; Atorvastatin ; Cardiovascular diseases ; Cholesterol ; Coenzyme Q10 ; CoQ 10 ; Creatine ; Creatine kinase ; Density ; Diet ; Glutathione ; Heart diseases ; High density lipoprotein ; High fat diet ; Lipoproteins ; Liver ; Liver damage ; Liver diseases ; Low density lipoprotein ; Malondialdehyde ; Muscles ; Myalgia ; Myopathy ; Nanoparticles ; Nanoparticulate ; Oxidative stress ; Particulates ; Quadriceps muscle ; Rats ; Rodents ; Statins ; Superoxide dismutase ; Tocopherol ; Transaminases ; Triglycerides ; Vitamin E</subject><ispartof>Life sciences (1973), 2018-06, Vol.203, p.129-140</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><rights>Copyright Elsevier BV Jun 15, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-d2dbdafd1b541aeb6cb6b9f07d7c2c3fd05be02c3dec85b0e0f5ded3a7c9f7a83</citedby><cites>FETCH-LOGICAL-c381t-d2dbdafd1b541aeb6cb6b9f07d7c2c3fd05be02c3dec85b0e0f5ded3a7c9f7a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lfs.2018.04.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29694831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Farrag, S.M.</creatorcontrib><creatorcontrib>Hamzawy, M.A.</creatorcontrib><creatorcontrib>El-Yamany, M.F.</creatorcontrib><creatorcontrib>Saad, M.A.</creatorcontrib><creatorcontrib>Nassar, N.N.</creatorcontrib><title>Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-particulate formulation in alleviating the muscles and liver damage either alone or when co-administered with nano coenzyme Q10 and nano vitamin E. Male Wistar rats were fed normal diet or high-fat diet for 12 weeks, following which rats were treated with either (i) atorvastatin (5 or 20 mg/kg/day, p.o.) or (ii) atorvastatin with CoQ10 (10 mg/kg/day, p.o.) (iii) and/or vitamin E (30 mg/kg/day, p.o.) in free particle or nanoparticle forms for another 4 weeks. In all rats, serum total cholesterol (CH), triglycerides (TGs), low (LDL) and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (ALP), creatine kinase (CK), albumin (ALB), as well as hepatic malondialdehyde (MDA) and antioxidants “reduced glutathione (GSH) and superoxide dismutase (SOD)” were measured. Additionally quadriceps muscles and liver tissues were used for histopathological examination. The antihyperlipidemic effect of statins was not altered when formulated as nanoparticles; albeit the former showed a prominent reduction in the liver and muscle enzymes and histopathological alterations together with a marked decline in the oxidative stress as compared to the free particulate form. These results were augmented when atorvastatin was combined with CoQ10 and/or Vit.E. Nanoparticulate formulation alleviated the statins induced liver and muscle damage especially when combined with CoQ10 and/or Vit.E.</description><subject>Alanine</subject><subject>Alkaline phosphatase</subject><subject>Antioxidants</subject><subject>Atorvastatin</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Coenzyme Q10</subject><subject>CoQ 10</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Density</subject><subject>Diet</subject><subject>Glutathione</subject><subject>Heart diseases</subject><subject>High density lipoprotein</subject><subject>High fat diet</subject><subject>Lipoproteins</subject><subject>Liver</subject><subject>Liver damage</subject><subject>Liver diseases</subject><subject>Low density lipoprotein</subject><subject>Malondialdehyde</subject><subject>Muscles</subject><subject>Myalgia</subject><subject>Myopathy</subject><subject>Nanoparticles</subject><subject>Nanoparticulate</subject><subject>Oxidative stress</subject><subject>Particulates</subject><subject>Quadriceps muscle</subject><subject>Rats</subject><subject>Rodents</subject><subject>Statins</subject><subject>Superoxide dismutase</subject><subject>Tocopherol</subject><subject>Transaminases</subject><subject>Triglycerides</subject><subject>Vitamin E</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc2KFTEQhRtRnOvoA7iRgBs33VPp9C-uhmH8gQERdB3SSYWbSzppk_Qdrk8yj2vaO7pwIQRSCd85VdQpitcUKgq0uzpUVseqBjpU0FTAmifFjg79WELH6NNiB1A3JauhvShexHgAgLbt2fPioh67sRkY3RUP18mHo4hJJONIPk44Xy4iJCNXKxIS7cO8VcY7Iqb8E8m8RmmRCKeINUcMRGhtjfyN3O_REemFxShRkXuT9vmJ7udpRvKVwqa68oEcTRJz7ne7Nd2fFgzWLEbhbCQJIsWXxTMtbMRXj_dl8f3D7bebT-Xdl4-fb67vSskGmkpVq0kJrejUNlTg1Mmpm0YNveplLZlW0E4IuVIoh3YCBN0qVEz0ctS9GNhl8e7suwT_Y8WY-Gzy5NYKh36NvAZGm5r2TZ3Rt_-gB78Gl6fLVE8ZNF3HMkXPlAw-xoCaL8HMIpw4Bb7Fxg88x8a32Dg0PMeWNW8enddpRvVX8SenDLw_A5hXcTQYeJQGXd6wCSgTV978x_4XN-ysew</recordid><startdate>20180615</startdate><enddate>20180615</enddate><creator>Farrag, S.M.</creator><creator>Hamzawy, M.A.</creator><creator>El-Yamany, M.F.</creator><creator>Saad, M.A.</creator><creator>Nassar, N.N.</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180615</creationdate><title>Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats</title><author>Farrag, S.M. ; Hamzawy, M.A. ; El-Yamany, M.F. ; Saad, M.A. ; Nassar, N.N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-d2dbdafd1b541aeb6cb6b9f07d7c2c3fd05be02c3dec85b0e0f5ded3a7c9f7a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Alanine</topic><topic>Alkaline phosphatase</topic><topic>Antioxidants</topic><topic>Atorvastatin</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Coenzyme Q10</topic><topic>CoQ 10</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Density</topic><topic>Diet</topic><topic>Glutathione</topic><topic>Heart diseases</topic><topic>High density lipoprotein</topic><topic>High fat diet</topic><topic>Lipoproteins</topic><topic>Liver</topic><topic>Liver damage</topic><topic>Liver diseases</topic><topic>Low density lipoprotein</topic><topic>Malondialdehyde</topic><topic>Muscles</topic><topic>Myalgia</topic><topic>Myopathy</topic><topic>Nanoparticles</topic><topic>Nanoparticulate</topic><topic>Oxidative stress</topic><topic>Particulates</topic><topic>Quadriceps muscle</topic><topic>Rats</topic><topic>Rodents</topic><topic>Statins</topic><topic>Superoxide dismutase</topic><topic>Tocopherol</topic><topic>Transaminases</topic><topic>Triglycerides</topic><topic>Vitamin E</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farrag, S.M.</creatorcontrib><creatorcontrib>Hamzawy, M.A.</creatorcontrib><creatorcontrib>El-Yamany, M.F.</creatorcontrib><creatorcontrib>Saad, M.A.</creatorcontrib><creatorcontrib>Nassar, N.N.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farrag, S.M.</au><au>Hamzawy, M.A.</au><au>El-Yamany, M.F.</au><au>Saad, M.A.</au><au>Nassar, N.N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2018-06-15</date><risdate>2018</risdate><volume>203</volume><spage>129</spage><epage>140</epage><pages>129-140</pages><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>Statins are the most widely used to lower elevated low-density lipoprotein levels and preventing cardiovascular diseases in humans. However, about 20% of patients treated with this medication suffer from statin-related myalgia. To this end, this study investigated the potential effect of nano-particulate formulation in alleviating the muscles and liver damage either alone or when co-administered with nano coenzyme Q10 and nano vitamin E. Male Wistar rats were fed normal diet or high-fat diet for 12 weeks, following which rats were treated with either (i) atorvastatin (5 or 20 mg/kg/day, p.o.) or (ii) atorvastatin with CoQ10 (10 mg/kg/day, p.o.) (iii) and/or vitamin E (30 mg/kg/day, p.o.) in free particle or nanoparticle forms for another 4 weeks. In all rats, serum total cholesterol (CH), triglycerides (TGs), low (LDL) and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST) transaminases, alkaline phosphatase (ALP), creatine kinase (CK), albumin (ALB), as well as hepatic malondialdehyde (MDA) and antioxidants “reduced glutathione (GSH) and superoxide dismutase (SOD)” were measured. Additionally quadriceps muscles and liver tissues were used for histopathological examination. The antihyperlipidemic effect of statins was not altered when formulated as nanoparticles; albeit the former showed a prominent reduction in the liver and muscle enzymes and histopathological alterations together with a marked decline in the oxidative stress as compared to the free particulate form. These results were augmented when atorvastatin was combined with CoQ10 and/or Vit.E. Nanoparticulate formulation alleviated the statins induced liver and muscle damage especially when combined with CoQ10 and/or Vit.E.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>29694831</pmid><doi>10.1016/j.lfs.2018.04.034</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2018-06, Vol.203, p.129-140
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_miscellaneous_2031421742
source ScienceDirect Journals (5 years ago - present)
subjects Alanine
Alkaline phosphatase
Antioxidants
Atorvastatin
Cardiovascular diseases
Cholesterol
Coenzyme Q10
CoQ 10
Creatine
Creatine kinase
Density
Diet
Glutathione
Heart diseases
High density lipoprotein
High fat diet
Lipoproteins
Liver
Liver damage
Liver diseases
Low density lipoprotein
Malondialdehyde
Muscles
Myalgia
Myopathy
Nanoparticles
Nanoparticulate
Oxidative stress
Particulates
Quadriceps muscle
Rats
Rodents
Statins
Superoxide dismutase
Tocopherol
Transaminases
Triglycerides
Vitamin E
title Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A18%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atorvastatin%20in%20nano-particulate%20formulation%20abates%20muscle%20and%20liver%20affliction%20when%20coalesced%20with%20coenzyme%20Q10%20and/or%20vitamin%20E%20in%20hyperlipidemic%20rats&rft.jtitle=Life%20sciences%20(1973)&rft.au=Farrag,%20S.M.&rft.date=2018-06-15&rft.volume=203&rft.spage=129&rft.epage=140&rft.pages=129-140&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2018.04.034&rft_dat=%3Cproquest_cross%3E2031421742%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2071304663&rft_id=info:pmid/29694831&rft_els_id=S0024320518302157&rfr_iscdi=true